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Abstract Treatment of melanoma cells by sodium arse-
nite or statins (simvastatin and lovastatin) dramatically
modified activities of the main cell signaling pathways
resulting in the induction of heme oxygenase-1 (HO-1) and
in a downregulation of cyclooxygenase-2 (COX-2) protein
levels. Through heme degradation and the production of
carbon monoxide and biliverdin, HO-1 plays a protective
role in different scenario of oxidative stress followed by
mitochondrial apoptosis. Both sodium arsenite and statins
could be efficient inducers of apoptosis in some melanoma
cell lines, but often exhibited only modest proapoptotic
activity in others, due to numerous protective mechanisms.
We demonstrated in the present study that treatment by
sodium arsenite or statins with an additional inhibition of
HO-1 expression (or activation) caused a substantial
upregulation of apoptosis in melanoma cells. Sodium
arsenite- or statin-induced apoptosis was independent of
BRAF status (wild type versus V600E) in melanoma lines.
Monotreatment required high doses of statins (20–40 lM)
for effective induction of apoptosis. As an alternative
approach, pretreatment of melanoma cells with statin at
decreased doses (5–20 lM) dramatically enhanced TRAIL-
induced apoptosis, due to suppression of the NF-jB and
STAT3-transcriptional targets (including COX-2) and
downregulation of cFLIP-L (a caspase-8 inhibitor) protein
levels. Furthermore, combined treatment with sodium
arsenite and TRAIL or simvastatin and TRAIL efficiently
induced apoptotic commitment in human neuroblastoma
cells. In summary, our findings on enhancing effects of
combined treatment of cancer cells using statin and TRAIL
provide the rationale for further preclinical evaluation.
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Regulation of the optimal levels of reactive oxygen species
(ROS) and suppression of oxidative stress in living cells
requires precise function of numerous protective mecha-
nisms, including induction of gene expression of several
antioxidant enzymes, such as catalase, superoxide dismu-
tase-2 (SOD-2), glutathione peroxidase, glutathione
reductase and heme oxygenase-1 (HO-1). Inducible HO-1,
as well as constitutive HO-2, catalyzes the first rate-limit-
ing step of heme degradation producing carbon monoxide
(CO) and biliverdin, which is further converted to bilirubin
that possesses strong anti-oxidant activity [1, 2]. Further-
more, CO inhibits enzymatic activities of numerous
hemoproteins resulting in downregulation of intracellular
respiration and ROS production. The ability of HO-1 to
catabolize free heme prevents induction of the mitochon-
drial apoptotic pathway that could operate as the final
resolution to maintain homeostasis at the whole organism
level via programmed death of particular cell populations
[3–5]. Since inflammation is often linked with high levels
of ROS production, the induction of HO-1 expression and
enzymatic activity is also involved in the protective anti-
inflammatory response [2, 6]. On the other hand, cancer
development and progression (including melanoma) is
linked with hypoxia, suppression of mitochondrial respi-
ration, increased production of ROS, which are inducers
of genomic instability, and establishing a general
pro-inflammatory phenotype that is maintained in cancer
cells through gene expression of the proinflammatory
cytokines, such as IL6, IL1b and TNFa and the corre-
sponding receptors [7]. Paradoxically, suppression of the
pro-inflammatory response of cancer cells could substan-
tially block tumor development [8] and sensitize cancer
cells to death receptor-mediated apoptosis [9].
In our previous investigations, we used sodium arse-
nite treatment (1–5 lM) for induction of apoptosis in
human melanoma cells [10, 11]. Similar treatment was
successfully used for therapy of acute promyelocytic
leukemia (APL) and multiple myeloma (MM) [12, 13].
However, the mitochondrial apoptotic pathway was
induced only at relatively low levels by clinically proved
concentrations (2–5 lM) of sodium arsenite in most
melanoma lines and required additional proapoptotic
sensitization through specific suppression of the cell
survival pathways, such as MEK-ERK, PI3K-AKT or
IKK-NF-jB [10, 11].
In recent years, effects of statins (popular drugs that are
widely used to down-regulate cholesterol production) on
mitochondrial function, ROS production and HO-1
induction have been extensively investigated [14, 15]. In
the present study, we further investigated a role of HO-1
suppression in the substantial upregulation of sodium
arsenite- or statin-induced cell death in human melanoma
cells. We found greater sensitization and killing of mel-
anoma cells through combined treatment of cancer cells
by the exogenous TRAIL and statins. Such dramatic
sensitization of TRAIL-Receptor (TRAIL-R) mediated
apoptosis by sodium arsenite [16] or by statins (the current
study) offers a new modality for a possible therapy of
melanoma, incident number of which progressively
increased in USA and worldwide during the last 50 years
[17].
In spite of the remarkable progress in the investigation
of carcinogenesis and treatment of melanoma based on the
application of specific inhibitors of permanently active
mutated BRAF (V600E) [18–20], there is a critical
necessity for alternative treatment of melanoma cells car-
rying wt BRAF (that represents 40–60% of melanoma
cases) [21] and for overcoming resistance to specific
inhibitors of BRAF (V600E) that could occur after several
months of a successful treatment.
Results
A role of HO-1 expression in protection of MEF against
sodium arsenite-induced apoptosis
To make a general assessment for a role of HO-1 induc-
ible expression in anti-apoptotic protection we used
HO1(HMOX1) Null mouse embryonic fibroblasts (MEF)
(Fig. 1a), which were previously established at Solomon
Snyder’s laboratory [22]. Using nuclear DNA staining by
PI and flow cytometry, we determined substantial differ-
ences in apoptotic response of HO1-deficient versus nor-
mal MEF 24 h after dose-dependent (2.5–20 lM) sodium
arsenite exposure. While 5 lM sodium arsenite induced
only a 2-fold increase in apoptosis in HO1-deficient cells,
10 lM sodium arsenite killed a vast majority of these
cells (Fig. 1b). LEHD-fmk, a specific inhibitor of caspase-
9, substantially suppressed levels of apoptosis induced by
10 lM arsenite, highlighting activation of the caspase-9
dependent mitochondrial apoptotic pathway, while the
effect of IETD-fmk, a caspase-8 and caspase-6 inhibitor,
on apoptosis was relatively modest. Finally, pan-caspase
inhibitor zVAD-fmk (50 lM) substantially blocked
apoptosis in both wt and HO1-deficient MEF induced by
10 lM sodium arsenite (Fig. 1c). Taken together, these
results indicated involvement of the mitochondrial path-
way and its substantial acceleration in HO1-deficient MEF
following sodium arsenite treatment. Although the role of
the mitochondrial pathway in mediation of arsenite-
induced apoptosis is well known [10, 23], establishing a
protective effect of HO-1 expression against arsenite-
induced apoptosis identified a new potential target for
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regulation of apoptosis not only in normal, but also in
cancer cells that are often characterized with highly
inducible HO-1 activation upon exposure to different
forms of stress.
Upregulation of sodium arsenite-induced apoptosis
in melanoma cells
Based on these results, we decided to upregulate sodium
arsenite-induced apoptosis in melanoma cells [10] using
additional suppression of HO-1. Sodium arsenite treat-
ment at low doses (2.5–5 lM), which was used success-
fully in the clinic for treatment of APL [24], induced high
protein levels of HO-1, while down-regulating protein
expression of cyclooxygenase-2 (COX-2/PTGS2), one of
the critical proinflammatory enzymes, in WM793, FEMX
and LOX human melanoma lines (Fig. 2a). However,
caspase-3 driven cleavage of PARP-1, a characteristic
feature of apoptotic commitment, was observed in
WM793 and FEMX, but not in LOX cells (Fig. 2a)
resulting in pronounced apoptosis for WM793 and FEMX
cells, but only G2/M arrest for resistant LOX cells 24 h
after treatment (Fig. 2b). This certainly indicated that
HO-1 activation was not the only critical factor that
determined a resistance to sodium arsenite. Beside HO-1
induction, multiple cell regulatory mechanisms, including
the basal AKT and NF-jB activities, could determine
differential response of melanoma lines to sodium arsenite
treatment [9–11]. Additional analysis of normal human
melanocytes, normal fibroblasts IMR-90 and several
melanoma lines confirmed our previous observations [10]
and demonstrated relatively low apoptotic levels in nor-
mal cells, as well as in LOX and WM9 melanoma cells,
while pronounced apoptosis in WM793 and FEMX mel-
anoma cells induced by 5–10 lM sodium arsenite treat-
ment. Apoptosis could be partially blocked by zVAD-fmk
(50 lM), a universal caspase inhibitor (Fig. 2c). Interest-
ingly, arsenite-induced apoptosis was independent on
BRAF mutation status: both WM793 [BRAF (V600E)]
cells and FEMX (BRAF wt) cells were sensitive to
sodium arsenite treatment (Fig. 2c).
Since sodium arsenite induced HO-1 transcription and
translation [25], we used a HO1-RNAi construct for stable
transfection and suppression of HO-1 expression in
WM793 melanoma cells. Control WM793 cells were
transfected with the empty vector pSR-GFP/Neo (Fig. 3a).
We observed that HO1-RNAi substantially suppressed
arsenite-induced HO-1 induction in transfected cells
(Fig. 3a). Sodium arsenite-induced PARP-1 cleavage (an
indication of caspase-3 activation) was detected in WM793
cells with suppressed HO-1 expression 6 h after treatment.
Levels of PARP-1 cleavage were notably increased in these
cells, compared to the control cells 12 h after treatment
(Fig. 3a). This was followed by a significant upregulation
of apoptotic levels for HO1 deficient cells that were
determined as % cells positively stained by Annexin-V-PE
(red) among GFP-positive permanently transfected
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Fig. 1 HO1 Null mouse embryonic fibroblasts (MEF) are very
sensitive to sodium arsenite induced death. aWestern blot analysis of
HO-1 induction by sodium arsenite in MEF. b. Cell cycle and
apoptosis analysis of wt and HO1 Null MEF, which were treated with
increased doses of sodium arsenite (2.5–20 lM), was performed using
PI staining of DNA and the flow cytometry. Apoptotic (pre-G1) levels
are indicated. c Down-regulation of arsenite-induced apoptosis
(10 lM) by specific caspase inhibitors, LEHD (a caspase-9 inhibitor),
IETD (a caspase-8 inhibitor), zVAD (a general caspase inhibitor)
used at dose 50 lM
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As an alternative approach to increase apoptotic
response, we used an inhibitor of enzymatic activity of
HO-1, Zn(II) containing Protoporphyrin IX [PPIX(Zn)].
Sodium arsenite (5 lM), in combination with PPIX(Zn) at a
dose of 20 lM, additionally increased (from 23 to 45%)
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Fig. 2 Induction of HO-1 protein expression and apoptotic commit-
ment in human melanoma cell lines after sodium arsenite treatment.
a Western blot analysis of protein levels of HO-1 and COX-2 6 h
after sodium arsenite (5 lM) treatment and PARP-1 cleavage 18 h
after sodium arsenite treatment of indicated melanoma lines. Actin
was used as a protein loading control. b Cell cycle and apoptosis
analysis 24 h after sodium arsenite treatment using PI staining of
DNA and the flow cytometry. Apoptosis (pre-G1) levels are indicated
for WM793, FEMX and LOX melanoma cells. G1 and G2/M levels
are indicated for LOX cells. Results of a typical experiment are
shown. c Cell death levels of normal human fibroblasts IMR-90,
human melanocytes and melanoma cell lines were determined 24 h
after sodium arsenite (5–10 lM) treatment in the presence or absence
of a caspase inhibitor zVAD (50 lM) using PI staining of DNA and
the flow cytometry. BRAF status (wt or V600E) of melanoma lines is
indicated. Error bars represent mean ± SD for four independent
experiments (Student’s t test, P\ 0.05)
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(Fig. 3c). The combination of 5 lM sodium arsenite and
20 lM PPIX(Zn) was most efficient for apoptotic induction
in several melanoma lines, including resistant LOX, while
relatively mild effects were observed in normal fibroblasts
and melanocytes (Fig. 3d, e). Hence, results of genetic and
enzymatic inhibition of HO-1 demonstrated substantial
upregulation of arsenite-induced apoptosis in human mel-
anoma cells. There was a narrow window of concentrations
of PPIX(Zn) (10–20 lM), when apoptotic response in
melanoma cells induced by 5 lM sodium arsenite in the
presence of PPIX(Zn) was substantially higher, than in
normal cells. An additional increase in a concentration of
PPIX(Zn) was quite toxic for normal cells and caused
massive cell death by necrosis. Taken together, these results
indicated that HO-1 activation was necessary, but not suf-
ficient for protection of melanoma cells against apoptosis
induced by sodium arsenite treatment. Suppression of
HO-1, however, was linked with substantial upregulation of
arsenic-induced apoptotic levels in human melanoma cell
lines.
Sodium arsenite treatment further sensitizes melanoma
cells to TRAIL-induced apoptosis: a probable role
for COX-2 downregulation
A vast majority of cancer cell lines exhibited low sensi-
tivity to treatment by TRAIL alone and required an addi-
tional sensitizer in combination with TRAIL [26]. We
previously demonstrated such a role for sodium arsenite as
a sensitizer for TRAIL-induced death via suppression of
cFLIP expression and additional upregulation of surface
expression of TRAIL-R2/DR5 in several human melanoma
lines, including WM793, WM9 and LU1205 [16]. As
expected, A375 human metastatic melanoma cells
(TRAIL-R2/DR5-positive) demonstrated a similar
response to combined treatment with TRAIL and sodium
arsenite (Fig. 4a). Inhibition of HO-1 enzymatic activity by
PPIX(Zn) did not notably affect apoptosis induced by
TRAIL, but decreased levels of (TRAIL ? sodium arse-
nite)-induced apoptosis in melanoma cells (Fig. 4b), dem-
onstrating a probable role of HO-1 in promoting activity of
HO-1 p32
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Fig. 3 Inhibition of HO-1 expression by specific RNAi or chemical
inhibition of HO-1 enzymatic activity by Zn(II) containing Protopor-
phyrin IX [PPIX(Zn)] dramatically increased sodium arsenite-induced
apoptosis in WM793 melanoma cells. a WM793 cells were perma-
nently transfected either with the empty vector pSR-GFP/Neo (Oli-
goengine) or with the specific HO1-RNAi construct (Oligoengine)
based on this vector. Western blot analysis was performed for
determination of HO-1 protein levels in the control and HO1 deficient
melanoma cells 6 h after sodium arsenite (As, 5 lM) treatment. PARP-
1 protein levels were determined 6 and 12 h after treatment. Beta-Actin
was used as a loading control. b The early apoptotic levels induced by
sodium arsenite treatment. Annexin-V-PE (red) staining of WM793
cells permanently transfected with the empty vector or withHO1-RNAi
(green) before and 6 h after sodium arsenite (5 lM) treatment were
determined using the flow cytometry. c, dCell cycle–apoptosis analysis
ofWM793 cells 24 h after treatmentwith sodiumarsenite (5–10 lM) in
the presence or absence of increased doses of PPIX(Zn) (10–40 lM). A
typical experiment is shown in (c). e Effects of PPIX(Zn) at the dose of
20 lM on up-regulation of apoptotic levels in human melanocytes and
melanoma lines. Apoptotic levels were determined using PI staining of
DNA and the flow cytometry.Error bars represent mean ± SD for four
independent experiments (Student’s t test, P\ 0.05)
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the death receptor-mediated apoptotic pathway. Sodium
arsenite/HO-1 was found to cause downregulation of anti-
apoptotic COX-2 protein levels (Fig. 2a). Furthermore,
HO-1 activation has been observed to inhibit enzymatic
activities of numerous hemoproteins, including COX-2,
through CO binding to the heme [5]. These data suggested
that COX-2 suppression mediated by sodium arsenite and
HO-1 might be additional factor for upregulation of
TRAIL-induced apoptosis. Indeed, an alternative inhibition
of COX-2 enzymatic activity by NS398 (50 lM) also
upregulated levels of TRAIL-induced apoptosis in WM9
and WM793 melanoma cells (Fig. 4c).
Statins as inducers of HO-1 expression and cell death
of cancer cells
To extend our observations regarding a regulatory role of
HO-1 for apoptotic signaling, we used statins as inducers of
HO-1 expression in melanoma cells. Statins are widely








































































Fig. 4 Sensitization of human
melanoma cells to TRAIL-
induced apoptosis by sodium
arsenite treatment. a Human
melanocytes (me-cytes) and
melanoma lines, WM793, WM9
and LU1205 and A375 were
treated by TRAIL (50 ng/ml),
sodium arsenite (As) (5–10 lM)
alone or in combination.
Apoptotic levels were
determined using PI staining of
DNA and the flow cytometry.
b Effects of PPIX(Zn) (20 lM)
on sodium arsenite- or TRAIL-
induced apoptosis in WM793
and WM9 cells 24 h after
treatment. c Effect of NS390
(50 lM), a COX-2 enzymatic
inhibitor, on TRAIL-induced
apoptosis in WM793 and WM9
cells
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they inhibit 3-hydroxy-3-methyl-glutaryl-CoA reductase
(HMG-CoA reductase), the rate-limiting enzyme, which
controls production of mevalonate, an intermediate of the
biosynthesis of cholesterol [27]. Furthermore, mevalonate
is a precursor of several lipid isoprenoid intermediates,
such as geranylgeranyl pyrophosphate (GGPP) and far-
nesyl pyrophosphate (FPP), which are critically important
for posttranslational modification and proper function of
small GTP-binding proteins, including Rho, Rac and Ras
that play pivotal role in cell signaling in normal and cancer
cells [28]. Furthermore, via control of cholesterol biosyn-
thesis and cell signaling, statins demonstrated a strong anti-
inflammatory potential that also included the induction of
HO-1 expression in different cell systems [14, 29].
Indeed, our data demonstrated that simvastatin at the
dose 10–40 lM strongly upregulated HO-1 expression in
WM793 and WM9 melanoma cells (Fig. 5a). Furthermore,
numerous effects of simvastatin treatment on signaling
proteins were observed in both melanoma lines with certain
quantitative differences: a dose-dependent inhibition of
ERK1/2 phosphorylation and activation; the absence of
inhibitory effects of simvastatin for phospho-AKT in
WM793 cells with high AKT activity and suppression of
AKT activity by high dose of simvastatin (40 lM) in WM9
cells with low AKT activity; suppression of the basal
STAT3 Tyr phosphorylation in WM9 cells by 40 lM
simvastatin. Furthermore, a dramatic downregulation of













































































Fig. 5 Dose-dependent effects
of simvastatin (SS) on cell
signaling pathways in WM793
and WM9 melanoma cells. a,
b Western blot analysis of
indicated proteins in WM793
and WM9 melanoma cells. c,
d Effect of simvastatin (SS) on
NF-jB-dependent luciferase
reporter activity and GAS/
STAT-dependent luciferase
activity (normalized to b-gal
activity) in transiently
transfected melanoma cells.
Control cells (0 lM SS) were
treated only with DMSO (at
final concentration 0.1%) that
was used for dissolving
simvastatin
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downregulation, was observed in both melanoma lines as a
result of simvastatin treatment (Fig. 5a, b). Simultaneously,
cleavage and activation of pro-caspase-8 and pro-caspase-9
was detected, which was also accompanied by a permanent
downregulation of cFLIP-L levels (a caspase-8 inhibitor)
and changes in the levels of its cleaved products 6 h after
statin treatment (Fig. 5a, b). At this time point, however,
only a mild decrease of the p116 subunit of PARP-1 (a
caspase-3 target) was detected. A pronounced cleavage of
Bid was also not observed (Fig. 5a, b). A role of the acti-
vation of the caspase-8-mediated pathway during statin-
induced apoptosis is not completely understood. However,
the basal production and secretion of TNFa [10] and surface
expression of the endogenous FasL [30] and TRAIL [16] in
melanoma cells potentially could be responsible for the
subsequent activation of the death receptor signaling path-
way under conditions where down-regulation of cFLIP-L
and COX-2 anti-apoptotic activities were induced by statin.
Determination of NF-jB-dependent and GAS/STAT-
dependent luciferase activity further demonstrated statin-
dependent suppression of the general NF-jB transacting
activity in both WM793 and WM9 cells. STAT-dependent
luciferase activitywas also suppressed inWM9 cells andwas
almost undetectable in the control and statin-treatedWM793
cells (Fig. 5c, d). In summary, these results demonstrate a
rapid sensitization of statin-treated cells to apoptosis through
both the endogenous and exogenous pathways due to
numerous changes in apoptosis-related proteins.
Indeed, simvastatin treatment at low doses (2.5 lM)
resulted in an increased ratio of G1/G2 and the subsequent
dose-dependent induction of apoptosis in WM793 and
WM9 melanoma cell populations (Fig. 6a–c). As expected,
a 50-fold excess of mevalonate, a downstream product of
the reaction catalyzed by HMG-CoA reductase, almost
completely suppressed simvastatin-induced apoptosis
(Fig. 6b), highlighting the specificity of simvastatin, as an
inhibitor of HMG-CoA reductase activity, for apoptotic
signaling. Interestingly, GGPP at significantly lower doses
(10 lM) also substantially blocked apoptosis in melanoma
lines (Fig. 6c), indicating a critical role of geranylated
small G-proteins in cell survival and protection against
apoptosis in melanoma cells.
Induction of apoptosis by atorvastatin in melanoma cells
was relatively low, compared to simvastatin (Fig. 6d). On
the other hand, the HO-1 inhibitor, 20 lMPPIX(Zn), further
upregulated levels of apoptosis induced by 20–40 lM ator-
vastatin and simvastatin in WM793 and WM9 melanoma
cells (Fig. 6d). In contrast, zVAD-fmk (50 lM), a universal
caspase inhibitor, substantially decreased levels of simva-
statin-induced apoptosis in melanoma cells (Fig. 6d). Using
control andHO1 deficientWM793 cells (see Fig. 2b)we also
observed upregulation of apoptotic levels in HO1 deficient
cells for a range of simvastatin concentrations (10–40 lM)
(Fig. 6e). In summary, these results demonstrate pronounced
statin-induced apoptosis (at high doses of statin) in WM793
and WM9 cells that could be further increased by suppres-
sion of HO-1 expression/activation. These data identified
HO-1 expression, which operated in concert with other
defensive mechanisms, as an important factor protecting
against statin-induced apoptosis. Interestingly, simvastatin
at relatively low concentration (5 lM) notably upregulated
arsenite induced apoptosis, possibly via inhibition of ERK
activation. U0126, a specific inhibitor of MEK-ERK path-
way, demonstrated a similar effect (Supplementary Fig. 1).
Melanoma cells produce and secrete a variety of cyto-
kines, including NF-jB-dependent IL1b, TNFa and IL6,
which are known as major proinflammatory cytokines and
regulators of cell proliferation and metabolism. These
cytokines could be potential targets of negative regulation
by statins, because statin treatment resulted in a down-
regulation of a general NF-jB-dependent transcription (see
Fig. 5c). Next we determined the effects of simvastatin on
production and secretion of proinflammatory cytokines in
cell growth media of melanoma lines. We observed pro-
nounced negative effects of simvastatin treatment on
secretion of TNFa and IL1b that were produced at very low
pg/ml concentration (Fig. 7a, b). In contrast, a relative
downregulation of IL6 secretion (produced at much higher
doses, ng/ml) by simvastatin into the WM9 cell media was
slight, but significant. A notable down-regulation of IL6
secretion was not observed for WM793 cells after simva-
statin treatment (Fig. 7c). The absence of downregulation
of IL6 secretion by simvastatin, but its effect on down-
regulation of IL1b was previously reported [31]. This
indicated that simvastatin treatment of cancer cells did not
affect, in some circumstances, well known pro-inflamma-
tory targets, such as IL6. As expected, the exogenous IL6
added at high concentration (100 ng/ml) to the cell media
downregulated apoptotic levels induced by simvastatin in
WM9, but not in WM793 melanoma cells (Fig. 7d).
We performed analysis of cell death induction by statins
in normal human fibroblasts IMR-90, human melanocytes
and several melanoma lines. Simvastatin at doses of
10–40 lM induced different levels of apoptosis in cancer
cell lines, in the range between 10 and 70% 24 h after
treatment: high levels of apoptosis were observed for
WM793, FEMX and WM9 melanoma lines, while a slight
response, which was similar to the response of normal
cells, was detected for WM35 and HHMSX melanoma
lines; a modest response was measured in WM164 and
WM852 melanoma lines (Fig. 7d). While lovastatin pro-
duced a similar induction of apoptosis, apoptotic effect of
atorvastatin (10–40 lM) was not well pronounced in
human melanomas (Supplementary Fig. 2). We would like
to highlight that WM793 and WM9 cells contain mutated
BRAF (V600E), while FEMX and WM852 cells have
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Fig. 6 Statins-induced apoptosis in WM793 and WM9 melanoma
cells. a Cell cycle-apoptosis analysis of simvastatin (SS) treatment on
WM793 melanoma cells. Percentage of cells at distinct phases of cell
cycle and apoptotic (pre-G1) levels were determined using PI staining
of DNA and the flow cytometry. Control cells (0) were treated only
with DMSO (at final concentration 0.1%) that was used for dissolving
simvastatin. b Suppression of simvastatin-induced apoptosis by
50-fold excess of mevalonate (Mev) that was added 15 min after
simvastatin (SS) into the cell culture of WM793 and WM9 cells.
c Effect geranylgeranyl pyrophosphate (GGPP) (10 lM) on
simvastatin-induced apoptosis in WM793 and WM9 cells. d Effects
of HO-1 inhibitor PPIX(Zn) on statin-induced apoptosis. Apoptosis
was initiated by atorvastatin (ATS), simvastatin (SS) (0–40 lM)
alone either in combination with HO-1 inhibitor PPIX(Zn), 50 lM, or
in combination with caspase inhibitor zVAD, 50 lM. e Apoptosis
levels in the control WM793-neo cells or in WM793 cells perma-
nently transfected with HO-1 RNAi that suppressed HO-1 expression.
Apoptotic levels were determined using PI staining of DNA and the
flow cytometry. Error bars represent mean ± SD for four indepen-
dent experiments (Student’s t test, P\ 0.05)
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normal BRAF [32]. Our results indicated that melanoma
cells with normal BRAF could also be treated and killed by
simvastatin at relatively high concentrations.
Statin doses routinely used for decreasing cholesterol
levels in human patients are 1–2 lM, while specific
apoptotic effects for some melanoma cell lines were well
pronounced only at doses 20–40 lM. Next we used statins
at lower doses (5–20 lM) in a combination with TRAIL
for an additional upregulation of TRAIL-induced apoptosis
in cancer cells.
Statin treatment sensitizes melanoma cells to TRAIL-
induced apoptosis
Melanoma lines used in the present study exhibited dif-
ferent levels of TRAIL-R2/DR5 surface expression, with
well pronounced expression in WM793, LU1205, WM9,
LOX and A375 cells; surface expression of TRAIL-R1/
DR4 was not well-defined [33, 34]. Based on similarity
between sodium arsenite and statins in the regulation of the
key signaling pathways and levels of apoptosis-related
proteins (such as cFLIP-L), we determined effects of
combined TRAIL and simvastatin treatment on apoptosis
in human melanoma lines. TRAIL alone (50 ng/ml) and
simvastatin alone (5–20 lM) could induce apoptosis at
different levels in distinct melanoma lines. The combina-
tion of TRAIL and simvastatin produced increased cas-
pase-3-mediated cleavage of PARP-1 by 4 h after
treatment of WM793 cells, when effect of the individual
inducers was not detectable (Fig. 8a). Both TRAIL and
simvastatin alone induced a modest PARP cleavage only
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Fig. 7 Dose-dependent effects
of simvastatin on apoptosis
levels in normal and cancer
cells. a–c IL1b, TNFa and IL6
levels (normalized for 100,000
cells) in culture medium of
melanoma WM793 and WM9
cells were determined 24 h after
simvastatin (SS) treatment by
ELISA. d Exogenous IL6
(100 ng/ml) down-regulated
simvastatin (SS)-induced
apoptosis in WM9 cells. e Doze-
dependent effect of simvastatin
(SS) on induction of apoptosis
in IMR-90 normal human
fibroblasts, melanocytes and
human melanoma lines was
determined using PI staining of
DNA and the flow cytometry.
BRAF status (wt or V600E) of
melanoma lines is indicated.
Control cells (SS, 0 lM) in all
lines were treated only with
DMSO (at final concentration
0.1%)
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was really strong at this time point (Fig. 8b). The maximal
dose-dependent effect of simvastatin on TRAIL-induced
apoptosis was occurred with 20 lM in WM793 and WM9
cells, although it was evident at 5 lM (Fig. 8c). Upregu-
lation of TRAIL-induced apoptosis by simvastatin, as well
as PARP-1 cleavage, was diminished in the presence of
50-fold excess of mevalonate (Fig. 8b, c), highlighting a
role of the inhibition of the mevalonate pathway for
upregulation of apoptosis. GGPP (10 lM) was an efficient
suppressor of TRAIL and simvastatin induced PARP-1
cleavage and apoptosis (Fig. 8b, c), indicating a critical
role of the remote downstream products of the mevalonate
biosynthetic pathway (that are vitally important for post-
translational modification of the Rac/Rho family members)
in the anti-apoptotic protection.
We further used a combination of TRAIL (50 ng/ml)
and simvastatin (20 lM) for upregulation of apoptosis in
additional melanoma lines (Fig. 8d). Normal fibroblasts
and melanocytes, as well as WM164 and HHMSX mela-
noma cells, exhibited low levels of apoptosis after a
combined treatment, due to low surface expression of































































































































Fig. 8 Sensitization of human
melanoma cells to TRAIL-
induced apoptosis by
simvastatin treatment. a,
b Western blot analysis of
PARP-1 cleavage in WM793
melanoma cells after TRAIL
(50 ng/ml) and simvastatin (SS,
20 lM) treatment in the
presence or the absence of
mevalonate (Mev, 1 mM) or
geranylgeranyl pyrophosphate
(GGPP, 10 lM). c, d Effect of
co-stimulation by simvastatin
(5–20 lM) on TRAIL-induced
apoptosis in normal (IMR-90
and melanocytes) and indicated
cancer cell lines. Apoptotic
levels (pre-G1) were determined
using PI staining of DNA and
the flow cytometry. Error bars
represent mean ± SD for four
independent experiments
(Student’s t test, P\ 0.05)
1278 Apoptosis (2011) 16:1268–1284
123
Author's personal copy
WM9 melanoma cells demonstrated enhanced apoptosis;
medium apoptotic induction was observed in WM35,
FEMX and WM852 cells (Fig. 8d). Additive effects of
combined treatment with TRAIL and simvastatin on
upregulation of apoptosis were likely dependent on several
parameters such as the level of TRAIL-R surface expres-
sion, efficiency of the death-inducing signaling complex
(DISC) formation [35], suppression of anti-apoptotic pro-
teins, cFLIP-L and COX-2, and changes in NF-jB- and
STAT3-dependent anti-apoptotic gene expression. Our
results highlighted the usefulness of combined treatment
for apoptotic induction in cell culture and could serve as a
basis for subsequent in vivo experiments.
Sodium arsenite or statin treatment sensitizes
neuroblastoma cells to TRAIL-induced apoptosis
Due to common origin from the embryonic neural crest,
there is a certain similarity in gene expression, regulation
of cell signaling pathways and apoptosis in melanocytes
and neurons [36] and probably in melanomas and neu-
roblastomas. Sodium arsenite was a powerful inducer of
HO-1 expression in human neuroblastoma HTB-11 cells
(Fig. 9a) similarly to the levels observed in melanoma cells
(see Fig. 2a). Sodium arsenite treatment also resulted in
PARP-1 116 kb down-regulation/cleavage (Fig. 9a) and in
induction of apoptosis in HTB-11 cells (Fig. 9b). Inhibition
of HO-1 enzymatic activity by PPIX(Zn) increased arse-
nite-induced apoptosis in both A375 melanoma and HTB-
11 neuroblastoma cells (Fig. 9c). Furthermore, HTB-11
cells demonstrated a pronounced response to combined
treatment by TRAIL and sodium arsenite (Fig. 9b, c).
PPIX(Zn) did not notably affect apoptosis induced by
TRAIL, but decreased levels of (TRAIL ? sodium arse-
nite)-induced apoptosis in melanoma and neuroblastoma
cells (Fig. 9b, c).
HTB-11 neuroblastoma cells were relatively resistant to
statin treatment at a dose range of 1–20 lM. However, a
combination of TRAIL (50 ng/ml) and simvastatin
(20 lM) or TRAIL and atorvastatin (20 lM) demonstrated
efficient for upregulation of apoptosis in HTB-11 neuro-
blastoma cells, compared to A375 melanoma cells
(Fig. 9d). In contrast to A375 cells, HTB-11 cells produced
and secreted high levels of the proinflammatory IL6.
Simvastatin treatment did not decreased IL6 levels in the
cell growth media, as we previously observed for WM793
cells (see Fig. 7c), indicating that anti-inflammatory effects
of simvastatin were limited.
Hence, results obtained demonstrated a significant
upregulation of TRAIL-mediated apoptosis by combined
treatment with simvastatin not only in melanoma, but also
in neuroblastoma cells.
Discussion
Melanoma is the fifth most common cancer in men and the
seventh most common cancer in women. It is estimated
that 68,130 people in the United States were diagnosed in
2009, and 8,700 died because of it (Melanoma Cancer
Overview by American Cancer Society, November 2010;
www.cancer.org). In spite of substantial progress in
understanding the molecular mechanisms of melanoma
carcinogenesis and extensive development of new treat-
ment modalities during the last 5 years, induction of
apoptotic commitment in metastatic melanomas and over-
coming resistance to new targeting treatment [for example
a resistance to specific BRAF (V600E) inhibitors] remain
significant problems [18, 37–39]. Our general expectation
was that combined treatment based on activation of the
TRAIL/TRAIL-R apoptotic pathway, which was quite
specific for cancer cells, together with metabolic inhibitors
could be potentially beneficial approaches for cancer
therapy. In the present study, we have been focused first on
suppression of inducible HO-1 activity that could result in
further upregulation of ROS-induced apoptosis in human
melanomas. Surprisingly, sodium arsenite and statins could
affect many common targets, exhibiting anti-inflammatory
effects through suppression of the IKK-NF-jB pathway
[40], its critical transcriptional target COX-2 [41] and a
dramatic induction of HO-1 activity. Stress-induced HO-1
activation is often a result of mitochondrial targeting fol-
lowed by release of heme-containing cytochrome c, which
should be degraded: holoenzyme through the proteasome
system [42] and heme by HO-1. Furthermore, HO-1 could
be further involved in the maintenance of the anti-inflam-
matory response by suppression of COX-2 enzymatic
activity and prostaglandin-E2 production. An alternative
pathway that operates in parallel, a cytochrome c interac-
tion with the apoptosome, results in the activation of the
caspase-9-dependent apoptotic pathway that ultimately
determines a life-or-death balance [43]. Even though our
results demonstrated enhanced upregulation of the mito-
chondrial apoptotic pathway by HO-1 suppression, a
challenging problem that remains is the absence of suitable
physiological inhibitors of HO-1, because Zn containing
PPIX (widely used in cell culture experiments) is cytotoxic
for in vivo treatment.
Our observations and published data also demonstrated
that monotreatment with statin induced pronounced apop-
totic death in some melanoma cell lines only at relatively
high doses (5–20 lM) [44]. Animal experiments with the
B16F10 mouse melanoma model exhibited a suppression
of tumor growth by treatment with 1.6 lM simvastatin
[45]. However, a regular statin treatment of patients for the
control of cholesterol levels appears does not display a
pronounced anti-melanoma protection [46, 47].
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Furthermore, multiple side effects of statin treatment for
normal cells linked with mitochondrial destruction, apop-
tosis and the subsequent myopathy were reported [48].
Therefore, solid evidence does not exist that statin mono-
therapy would be efficient for in vivo treatment.
An alternative approach was an upregulation of TRAIL-
induced apoptosis in melanoma cells with additional sen-
sitization of cancer cells by sodium arsenite [16] or statins
(in the present study). Specific inhibitors of IKK-NF-jB
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Fig. 9 Sensitization of HTB-11 human neuroblastoma cells to
TRAIL-induced apoptosis by sodium arsenite or simvastatin treat-
ment. a Western blot analysis of HO-1 induction and PARP-1 levels
in HTB-11 cells 16 h after sodium arsenite exposure. b A combined
treatment of sodium arsenite and TRAIL induced high levels of
apoptosis in HTB-11 neuroblastoma and cells. Apoptotic levels are
indicated. C. Effects of PPIX(Zn), 20 lM on sodium arsenite-induced
apoptosis and (TRAIL ? sodium arsenite)-induced apoptosis in
HTB-11 neuroblastoma and A375 melanoma cells. d A combined
treatment of statin and TRAIL significantly increased TRAIL-
mediated apoptosis in HTB-11 and A375 cells. Apoptotic levels
(pre-G1) were determined using PI staining of DNA and the flow
cytometry. Error bars represent mean ± SD for four independent
experiments (Student’s t test, P\ 0.05). e IL6 levels (normalized for
100,000 cells) in culture medium of melanoma A375 and neuroblas-
toma HTB-11 cells were determined 24 h after simvastatin (20 lM)
treatment using ELISA
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antiinflammatory response, specific inhibitors of pro-
inflammatory regulators, such as COX-2 inhibitors, and
more general inhibitors of the inflammatory response, like
resveratrol [33, 50], curcumin [51] and several others,
could be efficient sensitizers of cancer cells to TRAIL-
induced apoptosis. Statins with certain antiinflammatory
activities [29, 41] might play a similar role in upregulation
of death-receptor-mediated apoptosis in melanoma and
neuroblastoma cells. Costimulatory effects of statins on
TRAIL-induced apoptosis in glioblastomas [52] and on
FasL-mediated apoptosis of smooth muscle cells were
previously observed [53]. Interestingly, that through inhi-
bition of COX-2 activity, HO-1 alone had a proapoptotic
role in TRAIL-mediated apoptosis in melanoma cells. That
was in contrast to the antiapoptotic role of HO-1 in the
mitochondria-dependent apoptosis induced by sodium
arsenite or statins at higher doses. The proapoptotic effect
of HO-1 was very similar with NS398-mediated suppres-
sion of COX-2 activity, which also sensitized melanoma
cells to TRAIL-mediated apoptosis (see Fig. 4e). The
analogous effects of COX-2 inhibitors on TRAIL-induced
apoptosis in different cancer models were previously
described [54].
Even though proapoptotic effects of statins for mela-
noma cells have been previously reported in several pub-
lications [44, 55, 56], sensitization of melanoma cells to
TRAIL-induced apoptosis by statins, which was investi-
gated in our study, potentially could be a new modality for
melanoma therapy. It was especially important, that com-
bined treatment of statin and TRAIL was also quite
effective for killing BRAF wt melanoma cell lines, such as
WM852 and FEMX (see Fig. 8), where mutation specific
(BRAF V600E) inhibitors did not work.
Furthermore, numerous data are available about proa-
poptotic effects of arsenic [57], TRAIL alone and TRAIL
in different combinations for induction of apoptosis in
human neuroblastoma cells [50]. Combined treatment of
neuroblastoma cells with TRAIL and sodium arsenite or
TRAIL and simvastatin that was very efficient in our
in vitro study (see Fig. 9) might also serve as a potential
treatment modality for induction of high levels of apoptosis
in this type of tumor. In summary, our results further
highlighted significance of combined targeting of cell sig-




Sodium arsenite, simvastatin, atorvastatin, mevalonic acid
(lithium salt) and GGPP were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Human Killer-TRAIL was
purchased from Axxora (San Diego, CA, USA). Lovastatin
was purchased from Calbiochem/EMD Chemicals (San
Diego, CA, USA). COX-2 inhibitor NS398 was obtained
from Cayman Chemical (Ann Arbor, MI, USA). Human
recombinant IL6 was obtained from R&D Systems (Min-
neapolis, MN, USA). Zn(II) containing Protoporphyrin IX,
an inhibitor of HO-1, was purchased from Frontier Scien-
tific (Logan, UT, USA).
Cell culture
The primary human embryonic lung fibroblasts IMR-90
(Coriell Cell Repository, Camden, NY, USA) were main-
tained in medium supplemented with 15% fetal bovine
serum, vitamins, non-essential amino acids and antibiotics.
Normal human melanocytes were obtained from the
Department of Dermatology, Yale University (New Haven,
CT, USA) and maintained in TICVA medium. Human
melanoma cell lines LU1205 (also known as 1205lu),
WM9, WM35, WM164, WM793, WM852 [58], FEMX,
LOX, HHMSX [59] and A375 and human neuroblastoma
cell line HTB-11 (SK-N-SH) were maintained in DMEM
medium supplemented with 10% fetal bovine serum,
L-glutamine and antibiotics. Cells were grown at 37"C with
5% CO2. A375 and HTB-11 cell lines were obtained from
American Type Culture Collection (ATCC, Manassas, VA,
USA).
Transfection and luciferase assay
The NF-jB luciferase reporter containing two jB binding
sites, and STAT-Luc reporter containing three repeats of
GAS sites from the Ly6A/E promoter were used to
determine NF-jB and STAT transactivation, respectively.
Transient transfection of different reporter constructs
(1 lg) together with pCMV-b-galactosidase (0.25 lg)
into 5 9 105 cells was performed using Lipofectamine
(Life Technologies-Invitrogen, Carlsbad, CA, USA).
Proteins were prepared for b-Gal and luciferase analysis
16 h after transfection. Luciferase activity was deter-
mined using the Luciferase assay system (Promega,
Madison, WI, USA) and was normalized based on
b-galactosidase levels.
Apoptosis studies
Surface levels of TRAIL-R1/DR4 and TRAIL-R2/DR5
were determined by staining with the PE-labeled mAbs
from eBioscience (San Diego, CA, USA). A FACS Calibur
flow cytometer (Becton Dickinson, Mountain View, CA,
USA) combined with the CellQuest program was used to
perform flow cytometric analysis.
Apoptosis (2011) 16:1268–1284 1281
123
Author's personal copy
For induction of apoptosis, cells were exposed to sodium
arsenite (1–20 lM) or statin (1–80 lM) alone or in the
presence of protoporphyrin IX (ZnII) at a dose 10–40 lM.
Cells were also exposed to soluble TRAIL (50 ng/ml)
alone or in a combination with sodium arsenite (5 lM) or
simvastatin (5–20 lM). Apoptosis was then assessed by PI
staining and quantifying the percentage of hypodiploid
nuclei (pre-G1) using FACS analysis.
Western blot analysis
Total cell lysates (50 lg protein) were resolved on SDS-
PAGE, and processed according to standard protocols. The
monoclonal antibodies used for Western blotting included:
anti-b-Actin (Sigma, St. Louis, MO, USA); anti-FLIP
(NF6) (Axxora, San Diego, CA, USA); anti-caspase-8,
anti-caspase-9, anti-caspase-3 (Cell Signaling, Danvers,
MA, USA); anti-COX-2 (Cayman Chemical, Ann Arbor,
MI, USA). The polyclonal antibodies used included anti-
phospho-p44/p42 MAP kinase (Thr202/Tyr204) and anti-
p44/p42 MAP kinase; anti-phospho-AKT (Ser473) and
anti-AKT; anti-p65 NF-jB, anti-STAT3, anti-phospho-
STAT3 (Tyr705); anti-PARP-1; anti-Bid (Cell Signaling,
Danvers, MA, USA); anti-HO-1 (Enzo Life Sciences,
Plymouth Meeting, PA, USA). The secondary antibodies
were conjugated to horseradish peroxidase; signals were
detected using the ECL system (Thermo Scientific, Rock-
ford, IL, USA).
ELISA
Antibody pairs used in sandwich ELISA for this study were
all commercially available. Kits to detect IL6, TNFa and
IL1b were from Life Technologies/Invitrogen (Carlsbad,
CA, USA).
RNAi targeting of HO-1 mRNA
The empty vector pSR-GFP/Neo was obtained from Oli-
goengine (Seattle, WA, USA). RNAi of 19 nucleotides
(AGATTGCCCAGAAAGCCCT), designed to target
human HO-1 mRNA within nucleotides 526–544 were
expressed using pSR-GFP/Neo (HO-1-RNAi) plasmid
construct, which also produced a marker GFP protein.
Human melanoma cells WM793 have been used for HO-1
targeting. Melanoma cells were transfected with indicated
expression vectors using Lipofectamine (Life Technolo-
gies/Invitrogen, Carlsbad, CA).
For detection of apoptotic levels after treatment with
sodium arsenite or statin, GFP-positive stably transfected
cells were stained by PE-labeled Annexin-V (red) (BD-
Pharmingen, San Diego, CA, USA). A FACS Calibur flow
cytometer (Becton Dickinson, Mountain View, CA, USA)
combined with the CellQuest program was used to perform
flow cytometric analysis of double-stained cells.
Statistical analysis
Data from 3 to 4 independent experiments were calculated
as means and standard deviations. Comparisons of results
between treated and control groups were made by the
Students’ t tests. A P value of 0.05 or less between groups
was considered significant.
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